After successfully concluding the coronavirus vaccination campaign in four states, a similar mega-exercise will be carried out in all states and union territories on January 2.
This is aimed at equipping all administration and management of vaccine supply, storage and logistics, including cold chain management, the health ministry said on Thursday.
It is proposed that the activity be carried out in all state capitals at at least three session sites. Some states will also include districts in difficult terrain or with poor logistical support.
Maharashtra and Kerala are likely to schedule the dry run in major cities other than their capital.
“The objective of the dry trial for the introduction of the COVID-19 vaccine is to assess the operational feasibility of using the Co-WIN application in the field, to test the links between planning and implementation and identify challenges and guide the way forward before implementation, ”the ministry added.
For each of the three session sites, the medical manager concerned will identify 25 beneficiaries of the test (health workers). States and UTs have been requested to ensure that data from these beneficiaries is uploaded into Co-WIN.
These beneficiaries will also be available on the session site for the dry run. States and TUs were also urged to prepare the facilities and users to be created on the CoWIN app, including uploading beneficiary data from health workers (HCs).
States and TUs have been asked to ensure physical verification of all proposed sites to verify suitability of space, logistical arrangements, internet connectivity, electricity, security.
They were asked to prepare at least three model session sites in each state for demonstration, ensuring that model sites have separate entrance and exit in a “ three-room configuration ” with adequate space outdoors for outreach activities, post all CEI material on these sites.
Since vaccine administrators will play an important role in the immunization process, training of trainers and those who will administer the vaccine has been undertaken in various states. About 96,000 vaccinators have been trained for this purpose.
About 2,360 participants were trained in the national training of trainers and over 57,000 participants were trained in district level training in 719 districts. States are strengthening the 104 helpline, which will be used in addition to the 1075, for all vaccine and software related questions.
Orientation and capacity building for call center executives has taken place in the US and UTs. States were also encouraged to proactively use FAQs published by the Department of Health to answer such a question.
An important point of the dry trial will be the management of any possible adverse event after vaccination (AEFI). In addition, adherence to and management of infection control practices at the session site, to prevent disease transmission.
The mock exercise will include simultaneous monitoring and review at the block and district levels, as well as the preparation of feedback. The state working group will review the comments and share them with the Union Health Ministry.
On December 28 and 29, a Covid-19 vaccination trial was carried out in the Krishna district of Andhra Pradesh, Rajkot and the Gandhinagar district of Gujarat, Ludhiana and Shaheed Bhagat Singh Nagar of the Punjab and the districts of Sonitpur and Nalbari from Assam.
After a year that has seen an unprecedented global health crisis, many are anticipating the coronavirus vaccine as India prepares for the vaccination campaign, which is expected to begin in January 2021.
The central government plans to vaccinate nearly 30 million people in the first phase of the campaign. It will be offered to 1 crore of healthcare workers, as well as 2 crore of frontline and essential workers and 27 crore of elderly, mostly over 50 with comorbidities.
India currently has eight Covid-19 vaccine candidates, including three indigenous vaccines, in various stages of clinical trials that may be ready for authorization in the near future. The Covishield vaccines from Serum Institute-Oxford, Covaxin and Pfizer from Bharat Biotech are in the running for emergency use authorization.